Micronization and pre-blending of trimethadione veterinary-grade API for direct-compression tablets is constrained by the need for dose accuracy in low-weight veterinary patients. When the API is received with a particle-size distribution that is not suitable for uniform low-dose distribution, size reduction is performed in a spiral jet mill with compressed nitrogen at 6.0 bar to 8.0 bar and feed rate adjusted to keep mill outlet temperature below 40°C. The micronized material is then blended as a 1:10 geometric dilution with microcrystalline cellulose Ph. Eur. 101 through an 800 µm hand screen, followed by transfer to a 1 L bin blender operating at 10 rpm for 15 min. If agglomerates remain after storage, the pre-blend is passed through a 500 µm conical mill at 1 500 rpm. Final lubrication employs 0.5 wt% sodium stearyl fumarate mixed for 3 min at 15 rpm, rather than 1.0 wt% magnesium stearate, when ambient relative humidity exceeds 60%. Compression is performed on an instrumented eccentric tablet press with a target force of 12 kN to 18 kN and a speed not exceeding 30 rpm until force-displacement profiles confirm plastic deformation without capping. Tablet friability is measured per USP <1216>, and content uniformity is measured per USP <905> or Ph. Eur. 2.9.40. Because published data for trimethadione veterinary tablet compression is limited, the actual force range must be derived from development batches using each supplier lot and each target tablet diameter. The terminal dosage form is an immediate-release tablet or film-coated tablet for canine or feline neurology, with a hydroxypropyl methylcellulose Ph. Eur. 2910 coat applied if light protection, taste masking, or oesophageal transit is indicated.

What Changes When the Same API Is Prepared as a Multi-Dose Oral Solution Rather Than a Dry Powder?

Solution formulation shifts the control burden from powder flow and compressibility to equilibrium solubility, pH-dependent stability, dose uniformity, and preservative efficacy. Solubility screening is performed in water, 0.9% sodium chloride, and citrate-phosphate buffers at 25°C and 40°C using a shake-flask method with HPLC quantification; the resulting solubility curve determines whether co-solvents are required. If a co-solvent is used, propylene glycol or PEG 400 may be selected only after tissue tolerance and regulatory suitability are confirmed for the target species. Buffered vehicles are prepared with citric acid monohydrate and disodium phosphate; a development range of pH 4.0 to 6.0 is evaluated because oxazolidinedione ring stability can be pH-catalysed, but published stability data for trimethadione veterinary oral solutions is limited. Forced degradation studies per ICH Q1A(R2) and VICH GL3 are therefore required before fixing a shelf-life specification. Preservative-free formulations are possible only if dosing is restricted to single-use containers or if the product is designated as a dry powder for reconstitution. Multi-dose solutions typically require antimicrobial preservation confirmed by Ph. Eur. 5.1.3 or USP <51>; methylparaben sodium at 0.18% w/v and propylparaben sodium at 0.02% w/v are common starting levels, but the final choice must be validated for physical and chemical compatibility with the API and buffer salts. The solution is filled into amber Type III glass bottles with child-resistant closures if photostability testing indicates light sensitivity at the selected concentration. Delivered dose is verified by mass uniformity per USP <698> and by HPLC assay at release and at end of shelf-life. The terminal product is a 5 mg/mL to 20 mg/mL oral solution, with exact strength determined by target-species dose volume and body-weight banding rather than by analogy to human paediatric products.

Aseptic manufacturing of trimethadione injectable solution cannot assume that terminal steam sterilisation is compatible with the active molecule. The API is dissolved in Water for Injections USP/Ph. Eur., and if complete solubility is not reached at the intended concentration, a co-solvent such as propylene glycol or PEG 400 may be included only after regulatory acceptance in the target veterinary species. The solution is filtered through a 0.22 µm PVDF membrane at 20°C to 25°C under nitrogen pressure not exceeding 1.0 bar; filter compatibility is confirmed by assaying first, middle, and final filtrate fractions for API loss. Tonicity is adjusted with sodium chloride to 285 mOsm/kg to 310 mOsm/kg per USP <785> if the intended route is intravenous or intraperitoneal. The filled vials are stoppered with chlorobutyl rubber closures and sealed with aluminium flip-off caps; headspace oxygen is reduced to below 2.0% by nitrogen flushing if oxidative degradation is detected during forced degradation. Sterility is confirmed by USP <71> or Ph. Eur. 2.6.1, and bacterial endotoxin testing is performed per USP <85> or Ph. Eur. 2.6.14. Aseptic process simulations with sterile media must demonstrate zero growth across at least 3 consecutive runs before release. Because published thermal degradation kinetics for trimethadione in injectable vehicles is limited, terminal sterilisation at 121°C for 15 min should not be selected without a stability-indicating HPLC method validated per ICH Q2(R1). The terminal product is a single-dose or multi-dose injectable solution, with multi-dose presentations requiring preservative efficacy testing or a clear justification for absence of a preservative in the designated storage interval.

If a Medicated Feed Premix Is Required, Blend Uniformity and Carryover Control Are the Acceptance Drivers, Not Dissolution

Premix manufacture for trimethadione-containing medicated feed is governed by regional good manufacturing practice rules. In the United States, 21 CFR Part 225 establishes medicated feed cGMP; in the European Union, Regulation (EC) No 183/2005 and Regulation (EC) No 152/2009 define hygiene and analytical requirements. The API is first pre-blended with a carrier such as calcium carbonate or lactose monohydrate in a 500 L ribbon blender at 12 rpm for 20 min; the batch is then sampled at 10 points with a powder thief and assayed by HPLC. Typical release acceptance for uniformity is a coefficient of variation ≤5.0% with individual values within ±10% of the declared active concentration, but the exact criterion must follow the target-species marketing authorisation and the intended inclusion rate. Segregation risk is evaluated in a 6 m gravity drop test, comparing active content in top, middle, and bottom samples after discharge. Dust suppression is implemented with mineral oil at 0.5% to 1.0% by weight if a dustiness tester such as the Heubach Dustmeter indicates excessive fines under the selected carrier. The terminal product is a 0.1% to 5.0% w/w active premix packed in 25 kg multi-wall paper sacks with a polyethylene liner. Because medicated feed cross-contamination is a safety and trade issue, flushing with 10 kg of carrier after each batch is validated by rinse or swab assay below the analytical limit of quantification. Published data for trimethadione-specific premix carryover is limited; the flush volume, sequence, and sampling locations must be established during on-site validation under actual production humidity and bin-loading conditions.

Capsule Filling for Low-Dose Veterinary API Under Conditioned Environmental Control

Capsule filling is selected when dose adjustment for small companion animals is more reproducible than tablet splitting. The formulated powder blend is conditioned in a 25°C and 30% RH suite for at least 24 h before filling, because moisture uptake above 40% RH can change bulk density and dosator fill weight. On an automatic dosator capsule filler using size 2 or 3 gelatin capsules, fill weight is controlled by dosing chamber depth, powder bed height, and pre-compression setting; a compaction ratio of 1.2 to 1.6 is evaluated in development. The formulation relies on microcrystalline cellulose Ph. Eur. 102, pregelatinised starch, and 0.25 wt% fumed silica as glidant. Magnesium stearate is limited to 1.0 wt% and mixed for 3 min at 25 rpm because over-lubrication can delay dissolution in low-dose drug blends with limited water-soluble excipient content. Content uniformity is tested per USP <905>, and in vitro release is tested per USP <711> Apparatus 2 at 50 rpm in 900 mL 0.1 N HCl at 37°C. Capsules are packaged in PVC/PVDC/aluminium blisters if moisture protection is indicated; if HPMC capsules are used instead of gelatin, loss on drying is retested at the end of fill because HPMC shells can exchange moisture with the fill. The terminal product is a 10 mg to 50 mg capsule, with the exact strength justified by veterinary dose per kilogram and by available capsule fill-volume constraints. Published data for trimethadione veterinary capsule formulation is limited, so excipient ratios and fill parameters should be established by a design of experiments rather than by direct transfer from human-product templates.

When dry granulation is used to produce trimethadione granules for sachet or reconstitution, the measurable control points are ribbon density, granule size distribution, and residual moisture. Roller compaction is performed on a roller compactor with roll force 8 kN/cm to 12 kN/cm, gap 2 mm to 3 mm, and roll speed 5 rpm to 10 rpm; if the API is moisture-sensitive, dry granulation is preferred over wet massing. The compacted ribbons are milled through a 1.0 mm screen using a low-speed granulator, and fines below 75 µm are limited to 30% w/w to minimise segregation during packet filling. When wet granulation cannot be avoided, a high-shear mixer granulator is operated with a binder solution of pregelatinised starch 5.0% w/w added at 4.0% to 6.0% of dry mass. Endpoint is determined by impeller power consumption and impeller torque rather than time alone; drying in a fluid-bed dryer with inlet air at 60°C continues until loss on drying is 1.5% to 2.5%. If forced degradation shows thermal instability at 60°C, the inlet air temperature must be reduced or vacuum drying substituted. Granule flow is measured by Carr Index and Hausner ratio per USP <1174>, and content uniformity is tested per USP <905> on the final sachet or reconstituted dose. The terminal product is a single-dose granule in sachet or a bulk granule intermediate for further tablet or capsule compression; published data for trimethadione granulation thermodynamics is limited, so the thermal load must be confirmed by HPLC impurity profiling before scale-up.